General AML

Bruno Paiva | ASH 2018 | The role of MRD in redefining CR in elderly patients with AML

L: English
Watch Spanish version

Bruno Paiva from the University of Navarra, Pamplona, Spain talks about at the the 60th Annual Meeting of the American Society of Hematology (ASH), the findings of the phase III Pethema-Flugaza trial which aims to help define the role of MRD assessment by multidimensional flow cytometry (MFC) and its impact on therapeutic decision making in older AML patients treated with semi-intensive chemotherapy compared to hypomethylating agents (HMA). 

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!